Short-term efficacy of photobiomodulation in early and intermediate age-related macular degeneration: the PBM4AMD study.

PBM resulted in temporary improvements in visual function and a reduction in drusen volume, but these effects were not sustained at six months. The long-term efficacy and impact on disease progression are uncertain, necessitating further research to confirm these findings and determine optimal patient selection.